• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

渗出性年龄相关性黄斑变性中与过度“干性黄斑”相关的视力丧失。

Visual acuity loss associated with excessive "dry macula" in exudative age-related macular degeneration.

作者信息

Takahashi Hidenori, Inoue Yuji, Tan Xue, Inoda Satoru, Sakamoto Shinichi, Arai Yusuke, Yanagi Yasuo, Fujino Yujiro, Kawashima Hidetoshi

机构信息

Department of Ophthalmology, Jichi Medical University, Shimotsuke.

Department of Ophthalmology, The University of Tokyo, Bunkyo.

出版信息

Clin Ophthalmol. 2018 Feb 20;12:369-375. doi: 10.2147/OPTH.S151999. eCollection 2018.

DOI:10.2147/OPTH.S151999
PMID:29503524
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5824750/
Abstract

PURPOSE

To investigate the correlation between visual acuity and central macular thickness (CMT) and choroidal thickness (CCT) in patients with wet age-related macular degeneration (AMD).

METHODS

In this retrospective analysis, 14 eyes that received >10 ranibizumab injections (based on pro re nata [PRN] regimen) and maintained initial visual acuity gain were analyzed. The following 5 parameters were measured at the foveal center: CMT (distance from the inner limiting membrane [ILM] to Bruch's membrane); central retinal thickness (CRT; distance from the ILM to the inner limit of the retinal pigment epithelium or subretinal fluid [SRF]); SRF thickness (SRFT); pigment epithelium detachment thickness (PEDT); and CCT. The correlation between the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) and the 5 parameters was examined with generalized estimating equations.

RESULTS

CMT, CRT, and CCT were negatively correlated with logMAR BCVA (=0.031, 0.023, and 0.036, respectively) when only CMT values less than the thickness that maximized visual acuity for each eye were used for the analysis. Each 100-μm reduction in CMT, CRT, or CCT improved logMAR BCVA by -0.1, -0.08, or -0.07, respectively. SRFT and PEDT were not correlated with BCVA. The median CMT that maximized the visual acuity was 230 μm.

CONCLUSION

Dry macula with CMT <230 μm was associated with temporary decrease in visual acuity in AMD patients whose visual acuity was maintained with PRN regimen.

摘要

目的

研究湿性年龄相关性黄斑变性(AMD)患者的视力与中心黄斑厚度(CMT)及脉络膜厚度(CCT)之间的相关性。

方法

在这项回顾性分析中,对14只接受了超过10次雷珠单抗注射(基于按需[PRN]方案)并维持初始视力提高的眼睛进行了分析。在黄斑中心测量以下5个参数:CMT(从内界膜[ILM]到布鲁赫膜的距离);中心视网膜厚度(CRT;从ILM到视网膜色素上皮内界或视网膜下液[SRF]的距离);SRF厚度(SRFT);色素上皮脱离厚度(PEDT);以及CCT。使用广义估计方程检验最小分辨角对数(logMAR)最佳矫正视力(BCVA)与这5个参数之间的相关性。

结果

当仅使用每只眼睛中小于使视力最大化的厚度的CMT值进行分析时,CMT、CRT和CCT与logMAR BCVA呈负相关(分别为=0.031、0.023和0.036)。CMT、CRT或CCT每减少100μm,logMAR BCVA分别提高-0.1、-0.08或-0.07。SRFT和PEDT与BCVA无关。使视力最大化的CMT中位数为230μm。

结论

在采用PRN方案维持视力的AMD患者中,CMT<230μm的干性黄斑与视力暂时下降有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/c59bbd813db7/opth-12-369Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/6045378409b8/opth-12-369Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/3b5fe95b8ef9/opth-12-369Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/c59bbd813db7/opth-12-369Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/6045378409b8/opth-12-369Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/3b5fe95b8ef9/opth-12-369Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad04/5824750/c59bbd813db7/opth-12-369Fig3.jpg

相似文献

1
Visual acuity loss associated with excessive "dry macula" in exudative age-related macular degeneration.渗出性年龄相关性黄斑变性中与过度“干性黄斑”相关的视力丧失。
Clin Ophthalmol. 2018 Feb 20;12:369-375. doi: 10.2147/OPTH.S151999. eCollection 2018.
2
Comparison of one and three initial monthly intravitreal ranibizumab injection in patients with macular edema secondary to branch retinal vein occlusion.视网膜分支静脉阻塞继发黄斑水肿患者初始每月一次与每月三次玻璃体内注射雷珠单抗的比较
Int J Ophthalmol. 2018 Sep 18;11(9):1534-1538. doi: 10.18240/ijo.2018.09.17. eCollection 2018.
3
Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.眼内组织型纤溶酶原激活物、雷珠单抗联合气体注射治疗息肉样脉络膜血管病变伴黄斑下出血
Ophthalmology. 2016 Jun;123(6):1278-86. doi: 10.1016/j.ophtha.2016.01.035. Epub 2016 Mar 2.
4
CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.治疗糖尿病性黄斑水肿后中心脉络膜厚度的变化与中心黄斑厚度和最佳矫正视力的相关性。
Retina. 2018 May;38(5):970-975. doi: 10.1097/IAE.0000000000001645.
5
Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.色素上皮脱离,随后发生视网膜囊样变性,导致治疗新生血管性年龄相关性黄斑变性导致视力丧失。
Ophthalmology. 2015 Apr;122(4):822-32. doi: 10.1016/j.ophtha.2014.11.017. Epub 2015 Jan 9.
6
Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.日本患者玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性的五年治疗结果。
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1411-1418. doi: 10.1007/s00417-019-04361-8. Epub 2019 May 22.
7
Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.玻璃体内注射雷珠单抗与光动力疗法治疗特发性脉络膜新生血管:视力、视网膜及脉络膜厚度的对比研究
Chin Med J (Engl). 2014;127(12):2279-85.
8
Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.从按需治疗方案转换为治疗并延长方案可提高新生血管性年龄相关性黄斑变性患者的视力。
Acta Ophthalmol. 2017 Nov;95(7):678-682. doi: 10.1111/aos.13356. Epub 2017 Jan 31.
9
Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.根据“治疗并延长”方案,将渗出性年龄相关性黄斑变性的难治性眼转换为阿柏西普治疗后的两年功能和解剖学结果。
Acta Ophthalmol. 2017 Aug;95(5):460-463. doi: 10.1111/aos.13480. Epub 2017 May 29.
10
Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.中国内地人群接受“1+PRN”雷珠单抗治疗糖尿病性黄斑水肿的眼部解剖和功能反应:一年的结果。
BMC Ophthalmol. 2020 Jun 15;20(1):229. doi: 10.1186/s12886-020-01510-0.

引用本文的文献

1
6-month outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration and their relationships with clinical findings: a multicentre cohort study from the J-CREST.玻璃体内注射法西单抗治疗新生血管性年龄相关性黄斑变性的6个月结局及其与临床发现的关系:来自J-CREST的多中心队列研究
BMJ Open Ophthalmol. 2025 Sep 25;10(1):e002415. doi: 10.1136/bmjophth-2025-002415.
2
Retinal sensitivity above macular neovascularization under anti-VEGF therapy in exudative neovascular age-related macular degeneration.抗VEGF治疗下渗出性新生血管性年龄相关性黄斑变性患者黄斑新生血管上方的视网膜敏感性
BMC Ophthalmol. 2025 Mar 12;25(1):123. doi: 10.1186/s12886-025-03946-8.
3

本文引用的文献

1
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.视网膜下液在新生血管性年龄相关性黄斑变性患者治疗结局判定中的作用——一项雷珠单抗的IV期随机临床试验:FLUID研究
BMC Ophthalmol. 2016 Mar 24;16:31. doi: 10.1186/s12886-016-0207-3.
2
RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better.糖尿病性黄斑水肿治疗期间视网膜各层对雷珠单抗的反应:并非越薄越好。
Retina. 2016 Jul;36(7):1314-23. doi: 10.1097/IAE.0000000000000923.
3
IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL.
High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration.
在新生血管性年龄相关性黄斑变性中,进行高频 SD-OCT 随访,可使患者每两周接受一次玻璃体内雷珠单抗治疗。
Sci Rep. 2021 Mar 25;11(1):6816. doi: 10.1038/s41598-021-86348-2.
在采用治疗与延长方案对新生血管性年龄相关性黄斑变性进行积极治疗期间,复发性或残留性积液对视力的光学相干断层扫描的影响
Retina. 2016 Jul;36(7):1331-9. doi: 10.1097/IAE.0000000000000902.
4
REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome.玻璃体内注射雷珠单抗治疗新生血管性年龄相关性黄斑变性时的难治性视网膜内或视网膜下液:功能和结构结果
Retina. 2015 Jun;35(6):1195-201. doi: 10.1097/IAE.0000000000000465.
5
Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration.阿柏西普治疗新生血管性年龄相关性黄斑变性后脉络膜厚度的短期变化
Am J Ophthalmol. 2015 Apr;159(4):627-33. doi: 10.1016/j.ajo.2014.12.025. Epub 2014 Dec 30.
6
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.全球与年龄相关的黄斑变性患病率及 2020 与 2040 年疾病负担预测:系统回顾和荟萃分析。
Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3.
7
Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid.新生血管性年龄相关性黄斑变性伴慢性难治性黄斑中心凹下视网膜下液患者的视力保留情况
Saudi J Ophthalmol. 2014 Apr;28(2):129-33. doi: 10.1016/j.sjopt.2014.03.001. Epub 2014 Mar 12.
8
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.年龄相关性黄斑变性治疗试验比较中的地理萎缩风险。
Ophthalmology. 2014 Jan;121(1):150-161. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 29.
9
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.抑制年龄相关性脉络膜新生血管中 VEGF 的替代治疗:IVAN 随机对照试验的 2 年发现。
Lancet. 2013 Oct 12;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19.
10
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.年龄相关性黄斑变性治疗试验的黄斑形态和视力比较。
Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1.